Immunovant, Inc..
IMVT.US | Research and experimental development on natural sciences and engineering
Immunovant, Inc. is a biopharmaceutical company dedicated to developing and commercializing novel therapies for autoimmune diseases. The company focuses on developing IMVT-1401 (batoclimab), a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn), for the treatment of various aut...Show More
Better Health for All
0
No evidence available to assess Immunovant, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Immunovant, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
In 2025, Immunovant's CEO total compensation to median employee pay ratio was approximately 29 to 1.
1
The company's employee rating is 52 out of 100, which is in the 52nd percentile compared to peers and is trending down.
2
Glassdoor reviews show an overall rating of 2.6 out of 5 stars, which is significantly below the Pharmaceutical & Biotechnology industry average of 3.5 stars.
3
Only 41% of employees would recommend working at Immunovant, and 52% approve of the CEO.
4
Fair Trade & Ethical Sourcing
0
No evidence available to assess Immunovant, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-20
Immunovant has a whistleblower policy, adopted on December 18, 2019, which allows confidential and anonymous reporting via a website or phone, managed by an outside, independent service provider.
1
The Audit Committee oversees the receipt, retention, investigation, and response to all reports, and the company states it will not retaliate against whistleblowers.
2
The company has not reported any financial restatements in its quarterly reports as of June 30, 2025, or in its annual report for the fiscal year ended March 31, 2024.
3
The Audit Committee Charter, last amended April 2, 2024, requires Audit Committee members to satisfy independence requirements of the SEC and the Exchange.
4
However, an article from February 11, 2026, suggests the board's independence is questionable due to its entanglement with Roivant, whose interests are stated to dominate corporate decisions.
5
Immunovant's Audit Committee Charter, last amended April 2, 2024, states that the company shall implement and maintain an Anti-Corruption Policy.
6
The whistleblower policy also covers complaints relating to anti-corruption.
7
However, there is no evidence provided regarding the frequency of training or effectiveness metrics for this policy.
Kind to Animals
-50
Immunovant conducts animal studies for its drug candidates, including HL161ANS (IMVT-1402), as part of its research and development process.
1
The company's financial reports mention 'nonclinical studies' and 'pre-clinical studies' for its drug candidates.
2
However, there is no explicit animal testing policy disclosed by Immunovant in the provided information.
3
No War, No Weapons
0
Immunovant, Inc. is a biopharmaceutical company focused on developing therapies for autoimmune diseases, and the provided articles, primarily financial reports, confirm this business model.
1
The company does not currently manufacture or distribute approved drugs.
2
For all relevant KPIs, the evidence explicitly states 'Not applicable' or implies no involvement in defense, arms, or related activities due to the company's core business. Therefore, all applicable KPIs are scored as N/A, indicating no defense or arms-related activities in its core business, no dual-use products, no sales or exports requiring certification, no defense-related lobbying or procurement, no operations in conflict regions, no subject to ATT, no military use of AI, no human-rights risk exposures related to this value, no surveillance activities, no weapons red lines needed, and no exposure to weapons or defense assets to divest.
3
Planet-Friendly Business
0
Immunovant, Inc.'s annual report from March 31, 2020, explicitly states that no environmental data is provided for any of the relevant KPIs, including emissions, renewable energy, water usage, waste diversion, or environmental compliance.
1
No data is available regarding climate targets, certifications, or environmental impact assessments.
2
An ESG summary from Sustainalytics notes a high ESG risk for the company and weak management of ESG material risk, but it does not provide specific quantitative data for any of the planet-friendly business metrics.
3
Respect for Cultures & Communities
0
The provided articles, including ESG data summaries from Sustainalytics and CSRHub, and company information from Immunovant.com and Statnews.com, explicitly state that they do not contain specific quantitative data or details relevant to Immunovant, Inc.'s performance regarding 'Respect for Cultures & Communities'. No information was found on formal partnerships, community reinvestment, cultural incidents, impact assessment protocols, local employment, grievance mechanisms, FPIC processes, community governance, cultural preservation investment, local procurement, indigenous suppliers, cultural site protection, social license, charitable giving, community fund allocation, language inclusivity, cultural incident response, or cultural training completion.
1
Safe & Smart Tech
-10
Immunovant provides annual and ad hoc cybersecurity awareness training to all employees.
1
The company mentions encryption of data as a security measure and states that vulnerability management is part of its cybersecurity program.
2
It also conducts penetration and vulnerability tests, along with internal and external audits.
3
The company's clinical trials privacy policy indicates compliance with EU GDPR, UK GDPR, and US financial disclosure regulations.
4
However, data from clinical trials may be retained for up to 25 years post-trial, which is a lengthy retention period.
5
Zero Waste & Sustainable Products
0
No specific, quantitative data on waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education is provided for Immunovant, Inc. across the available articles.
1
The documents primarily focus on financial reporting or general ESG risk assessments, with explicit statements of data gaps for Immunovant regarding zero waste and sustainable product metrics.
2